Qilu Pharmaceutical
Large vertically-integrated Chinese pharma (FDF + API manufacturer)
Privately held: no public share price · China
Assets
(22 total)
22Total Assets
0Approved
14Phase 3 / Filed
8Phase 1–2 / Early
13Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | AKT (inhibitor)Small molecule | Breast Cancer HR+/HER2- Metastatic Breast Cancer | |
| Phase 3 | Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist) · Dopamine D3/D2 receptor (partial agonist)Small molecule | Schizophrenia | |
| Phase 3 | PD-1Monoclonal antibody | Indication not yet linked | |
| Phase 3 | PD-1 x CTLA-4Multispecific antibody | Non-Small Cell Lung CancerColorectal Cancer Metastatic Colorectal Cancer | |
| Phase 3 | ALK;ROS1Small molecule | Non-Small Cell Lung Cancer | |
| Phase 3 | Dopamine D2 and serotonin 5-HT2A/5-HT2C receptors (antagonist); mu-opioid receptor (antagonist) · Dopamine D2 and serotonin 5-HT2A receptors (antagonist)Small molecule | Schizophrenia | |
| Phase 3 | IL-23 p19Monoclonal antibody | Psoriasis | |
| Phase 3 | IL-4R-alphaMonoclonal antibody | Atopic Dermatitis | |
| Phase 3 | CD38Monoclonal antibody | Multiple Myeloma | |
| Phase 3 | PCSK9RNA / oligonucleotide | Atherosclerotic Cardiovascular Disease | |
| Phase 3 | JAKSmall molecule | Atopic Dermatitis | |
| Phase 3 | GPRC5D x CD3Multispecific antibody | Multiple Myeloma | |
| Phase 3 | GPRC5D x BCMA x CD3Multispecific antibody | Multiple Myeloma | |
| Phase 3 | GLP-1/GIP receptor (dual)Peptide | ObesityType 2 Diabetes | |
| Phase 2 | IRAK4Small molecule | Atopic Dermatitis |
Upcoming events
(32 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (3)
2027 (18)
February 2027 (1)
Est. primary completion 2027-02-28 · NCT07172217 · CT.gov ↗
What to watch
March 2027 (1)
April 2027 (2)
Iparomlimab and tuvonralimab + QLS5132Phase 1/2Gastric Cancer (GC), Non-small Cell Lung Cancer (NSCLC), Endometrial Cancer, Advanced Solid Tumors, Ovarian Cancer
Est. primary completion 2027-04 · NCT07453394 · CT.gov ↗
What to watch
May 2027 (1)
June 2027 (3)
August 2027 (1)
Est. primary completion 2027-08-31 · NCT05487391 · CT.gov ↗
What to watch
September 2027 (2)
October 2027 (1)
November 2027 (1)
2028 (6)
2029 (3)
June 2029 (1)
Est. primary completion 2029-06 · NCT05690945 · CT.gov ↗
What to watch
December 2029 (2)
Regulatory and conference events
(6)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
CN · Guangdong Zhongsheng Pharmaceutical (SZSE 002317), parent of Guangdong Raynovent Biotech · Source ↗
CN, NMPA · Laekna · Source ↗
15 April 2026Topline resultAfuresertibAFFIRM-205 Phase 3 (NCT04851613) met its primary endpoint of PFS
Laekna · Source ↗
6 December 2023Topline resultIparomlimab (QL1604)Qilu reports the pivotal Phase 2 result of iparomlimab in dMMR/MSI-H solid tumors (ORR 45.8%)
Qilu Pharmaceutical · Source ↗
September 2023Filing acceptedIparomlimab (QL1604)China's CDE accepts the new drug application for iparomlimab in dMMR/MSI-H solid tumors
CN, NMPA · Qilu Pharmaceutical · Source ↗
Financial reports
No financial reports recorded.